Overview

IFM 99-02 Thalidomide in Myeloma

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Toulouse
Treatments:
Diphosphonates
Thalidomide